INTERIM REPORT JANUARY–JUNE 2009

CONTINUED FOCUS ON CORE PROJECTS

The period January-June in brief • Net sales amounted to MSEK 4.4 (7.2), whereof the second quarter MSEK 2.2 (5.5) • Net loss decreased to MSEK 82.7 (101.8), whereof the second quarter MSEK 36.8 (49.9) • Loss per share decreased to SEK 0.71 (0.88), whereof the second quarter SEK 0.32 (0.43) • Cash flow from operating activities amounted to MSEK -79.6 (-105.7), whereof the second quarter MSEK -38.6 (-49.7) • Cash and cash equivalents and other short-term investments totaled MSEK 156.3 (329.2) at the end of the period • At The Annual American College of Cardiology Meeting in Orlando, Florida, March 29, 2009, results from Karo Bio’s phase IIb study with eprotirome as add-on to statin treatment were presented • In March, positive results from the phase I program with KB3305 were reported. In addition to healthy volunteers, a group of type 2 diabetes patients was included in the trials • The collaborative effort with Zydus Cadila have made several breakthroughs that increase the possibilities of finding suitable substances for further development into candidate drugs For further information, please contact: Per Olof Wallström, President, tel. +46 8 608 60 20 Erika Söderberg Johnson, Chief Financial Officer, tel. +46 8 608 60 52